Biomerica Inc (BMRA)vsEdwards Lifesciences Corp (EW)
BMRA
Biomerica Inc
$1.62
+5.88%
HEALTHCARE · Cap: $4.94M
EW
Edwards Lifesciences Corp
$88.97
-0.70%
HEALTHCARE · Cap: $49.56B
Smart Verdict
WallStSmart Research — data-driven comparison
Edwards Lifesciences Corp generates 150404% more annual revenue ($6.51B vs $4.33M). EW leads profitability with a 15.4% profit margin vs -96.5%. EW earns a higher WallStSmart Score of 55/100 (C).
BMRA
Avoid26
out of 100
Grade: F
EW
Buy55
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for BMRA.
Margin of Safety
+69.3%
Fair Value
$257.97
Current Price
$88.97
$169.00 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Strong operational efficiency at 29.8%
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -125.8% — below average capital efficiency
Expensive relative to growth rate
Weak financial health signals
Premium valuation, high expectations priced in
Earnings declined 25.4%
Comparative Analysis Report
WallStSmart ResearchBull Case : BMRA
The strongest argument for BMRA centers on Price/Book, Debt/Equity.
Bull Case : EW
The strongest argument for EW centers on Altman Z-Score, Operating Margin. Profitability is solid with margins at 15.4% and operating margin at 29.8%. Revenue growth of 13.6% demonstrates continued momentum.
Bear Case : BMRA
The primary concerns for BMRA are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : EW
The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 51.2x leaves little room for execution misses.
Key Dynamics to Monitor
BMRA profiles as a turnaround stock while EW is a mature play — different risk/reward profiles.
EW carries more volatility with a beta of 0.85 — expect wider price swings.
EW is growing revenue faster at 13.6% — sustainability is the question.
BMRA generates stronger free cash flow (-1M), providing more financial flexibility.
Bottom Line
EW scores higher overall (55/100 vs 26/100), backed by strong 15.4% margins and 13.6% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Biomerica Inc
HEALTHCARE · MEDICAL DEVICES · USA
Biomerica Inc. (Ticker: BMRA) is an innovative biotechnology firm focused on developing and manufacturing cutting-edge diagnostic solutions catering to both medical and food industries. The company specializes in proprietary testing methods aimed at metabolic diseases, gastrointestinal disorders, and food intolerances, positioning itself to significantly enhance healthcare outcomes and diagnostic precision. With a commitment to addressing unmet medical needs, Biomerica capitalizes on strategic research partnerships and advanced technology integration, facilitating growth in the dynamic diagnostics market. Its patient-centric strategy further underscores the potential for transformative improvements in global healthcare diagnostics, making it a compelling prospect for institutional investors.
Visit Website →Edwards Lifesciences Corp
HEALTHCARE · MEDICAL DEVICES · USA
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?